Article

Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation.

Department of Pediatrics, The Catholic University of Korea, College of Medicine, Seoul, Korea.
International Journal of Hematology (Impact Factor: 1.68). 12/2004; 80(4):370-6. DOI: 10.1532/IJH97.A30409
Source: PubMed

ABSTRACT Marrow stromal cells (MSC) produce a microenvironment supporting hematopoiesis and may contribute immune tolerance because of low immunogenicity and the suppressive effect of alloreactivity. We investigated whether cotransplantation of MSC could prevent lethal graft-versus-host disease (GVHD) in major histocompatibility complex mismatched allogeneic murine hematopoietic stem cell transplantation (HSCT) using female BALB/c (H-2d, recipient) and C3H/He (H-2k, donor) mice. MSC were obtained from C3H/He bone marrow cells (BMC). MSC and irradiated BALB/c splenocytes (SP) were cocultured with C3H/He SP or BMC. Nonirradiated MSC did not inhibit the proliferation of alloantigen-stimulated BMC and SP. However, irradiated MSC suppressed the proliferation of alloantigen-stimulated SP at a level comparable with that of immunosuppressive agents, and the suppression by MSC was reversed to a significant degree by interleukin 2. Lethally irradiated BALB/c mice received transplants of donor cells according to the following experimental groups (group A, BMC only; group B, BMC and SP; group C, BMC, SP, and MSC; group D, BMC and MSC). The survival rate in group D was higher than in the other groups (P = .0057), and the clinical GVHD scores and serum levels of interferon-gamma were low in group D. Our results suggest that cotransplantation of MSC in HSCT prevents lethal GVHD, possibly by immune modulation.

0 Bookmarks
 · 
64 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although the immunomodulative properties of mesenchymal stem cells (MSCs) open up attractive possibilities in solid-organ transplantation, information concerning the optimal dose, route, timing of administration, major histocompatibility complex (MHC)-restriction and relevant mechanisms is currently lacking. Therefore, better characterization of MSC immunoregulatory activity and elucidation of its mechanisms are crucial. In this study, we confirmed that MSCs did not elicit proliferation by allogeneic CD4(+) T cells, suggesting that MSCs were not immunogenic. By using C57BL/6 mouse MSCs as donor-derived or recipient-derived or as third-party MSCs, we discovered that MSCs suppressed CD4(+) T cell proliferation and prolonged mouse cardiac allograft survival in a dose-dependent and non-MHC-restricted manner. We also found that intraperitoneal administration favored survival prolongation, although this prolongation was weaker than that via the intravenous route. Only infusion at earlier time points favored survival prolongation. Depletion of CD4(+)CD25(+) T cells did not affect the immunosuppression of MSCs on CD4(+) T cells. Moreover, MSCs did not induce regulatory T cells. The in vivo data revealed that MSCs did not increase the percentage of CD4(+)CD25(+) T cells and FoxP3 expression. More importantly, we demonstrated for the first time that depletion of CD4(+)CD25(+) T cells did not hinder MSC-induced survival prolongation, indicating that CD4(+)CD25(+) regulatory T cells were not essential for the prolongation of MSC-mediated allograft survival.
    Cell and Tissue Research 08/2014; 358(2). DOI:10.1007/s00441-014-1956-z · 3.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) are being widely studied as potential cell therapy agents due to their immunomodulatory properties, which have been established by in vitro studies and in several clinical trials. Within this context, mesenchymal stem cell therapy appears to hold substantial promise, particularly in the treatment of conditions involving autoimmune and inflammatory components. Nevertheless, many research findings are still contradictory, mostly due to difficulties in characterization of the effects of MSCs in vivo. The purpose of this review is to report the mechanisms underlying mesenchymal stem cell therapy for acute graft-versus-host disease, particularly with respect to immunomodulation, migration, and homing, as well as report clinical applications described in the literature.
    Human Cell 06/2014; 27(4). DOI:10.1007/s13577-014-0095-x · 1.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Mesenchymal stromal cells (MSCs) are a unique cell type that has strong anti-proliferative effects on co-cultured activated T and B-cells in vitro. Based on our observation of significant differences between rheumatoid arthritis (RA) and osteoarthritis (OA) bone marrow B-cell compartments, we hypothesized that RA bone marrow MSCs may contribute to the pathogenesis of RA by enhancing B-cell survival.Objectives To compare the effect of RA and OA bone marrow derived MSCs (RA-MSCs, OA-MSCs) on the survival of healthy donor purified B-cells.MethodsRA-MSCs (n=7) and OA-MSCs (n=5) were isolated from patients undergoing hip replacement surgery, and cultured in vitro for 2-5 passages. Washed cells were co-cultured with CD20+ B-cells for 60 hours in 17 different co-culture experiments. Cell survival was analyzed using 7-amino-actinomycin D (7AAD) labelling and flow-cytometric analysis and compared to the survival of B-cells cultured without MSCs (n=8). Expression of B-cell activating factor (BAFF) mRNA and protein was determined by RT-PCR and flow-cytomery after labelling with BAFF-specific antibodies.ResultsWe observed that the presence of both RA-MSCs and OA-MSCs in the cultures significantly enhanced B-cell survival (70,11±7,28% and 54,65±11,83% viable cells, respectively) as compared to controls (35,13±13,83%, p < 0,001, Kruskal-Wallis ANOVA), the effect being more prominent in RA-MSCs (p < 0,05, Tukey-Kramer test). Both RA-MSCs and OA-MSCc displayed expression of BAFF mRNA and protein. We did not observe a convincing enhancement of BAFF mRNA expression by TNF-α. Blocking BAFF signalling by specific BAFF and BAFF-R antibodies, reduced the survival of B-cells by 20%, but did not abrogate the positive effect of MSCs on B-cell survival.ConclusionsMSC interaction with B-cells may provide additional stimuli for lymphocyte survival via an as yet unidentified factor and therefore contribute to the pathogenesis of RA. BAFF, though produced by MSCs, is of minor importance in this setting. Further studies to identify the molecular basis of our observation are warranted.
    Joint Bone Spine 03/2008; 75(2):243-243. DOI:10.1016/j.jbspin.2008.01.005 · 3.22 Impact Factor